Molar Pregnancy and Gestational Trophoblastic Disease

Brad Quade, M.D., Ph.D. Chief of Perinatal Pathology









Conflict of Interest Disclosure

None

Goals

- Molar Pregnancy and Gestational Trophoblastic Disease
 - Highlight molar gestations in their pathobiological context
 - Define the histologic and genetic features that distinguish molar gestation from each other and their mimics
 - Provide a practical strategy for pathologic diagnosis that leverages your available ancillary tools

• Breaking News: COVID-19 in Pregnancy

- Review the pathobiology of SARS-CoV-2 infection in the placenta and its clinical implications
- Define the features of COVID-2 placentitis

Molar Pregnancy – Key Concepts



• Products of conception

- Genetically distinct from the host in which they reside
- Arise most frequently from genetic errors occurring in fertilization
- Like normal trophoblasts, invade tissue and blood vessels
- Nosologic organization begins with presence or absence of villi
- Phenotypes resemble cells constituting the normal placenta
- Must be considered in the spectrum of trophoplastic neoplasia



Nosology Of Trophoblast Neoplasia

Tumor	Fetus	Cyto- trophoblast	Syncytio- trophoblast	Intermediate (Implantation Site) Trophoblast	Chorionic Membrane Trophoblast	Villi	Biological Potential	Primary Differential Diagnosis	Typical Genetics
Partial Hydatidiform Mole	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	~	?	Aneuploidy (+18), Complete Mole +/- co- twin, Mesenchymal Dysplasia, Beckwith-Wiedemann Syndrome	3n with diandry (2p1m)
Complete Hydatidiform Mole		\checkmark	\checkmark	\checkmark		\checkmark	Invasive & Metastatic	Hydropic Abortus, Partial Mole	2n with diandry (2p)
Chorio-carcinoma	\checkmark	\checkmark	\checkmark				Invasive & Metastatic	Other High Grade Neoplasm	Diploid, possibly diandric
Placental Site Trophoblast Tumor (PSTT)	\checkmark			\checkmark			Invasive & Metastatic to Lungs, pelvis, LNs (30-50%)	"Exaggerated" & Molar Implantation	46, <u>XX</u>
Epithelioid Trophoblast Tumor	\checkmark				\checkmark		Invasive	SCC of cervix ?De-diff. C	46, <u>XX</u>

Risk Factors For Trophoblastic Neoplasia

- Maternal Age
 - < 20 y/o RR = 1.5
 - >40 y/o RR = 5.2
- Race/Ethnicity
 - Indonesia Incidence = 1:85
 - Japan Incidence = 1:522
 - Incidence = 1:1560
 - USA

• Sweden

- Incidence = 1:1724
- Asian women in the USA have a higher risk than other ethnic groups
- Prior Molar Pregnancy, especially >1
- Nulliparity
- Low socioeconomic status

(best studied in complete hydatidiform mole)

Choriocarcinoma (ChorioCA)

The Foundation Of Trophoblastic Neoplasia





Choriocarcinoma – Clinical Context

- Gestational association:
 - 50% molar (complete >> partial)...but only 1 in 40 molar pregnancies
 - 25% spontaneous abortion
 - 2.5% ectopic gestation
 - 22.5% normal pregnancies (most often in 3rd trimester)
- Time Interval
 - Late -- many years (report of 14 yr)
 - Early -- concurrent (intraplacental choriocarcinoma)

Choriocarcinoma- Diagnosis







- Gross features
 - Hemorrhagic nodule(s)
 - Sampling of blood clot...particularly at the periphery
- Histological features
 - Biphasic (all cytokeratin +, GATA3)
 - Cytotrophoblasts and intermediate trophoblasts
 - Syncytiotrophoblasts (strong + for β -HCG, weak for HPL)
 - Caveat: may be infrequent in some tumors, possibly reduced following chemoTx
 - Hemorrhage and necrosis may predominate



Choriocarcinoma with hemorrhagic necrosis



Choriocarcinoma During Pregnancy:

Intraplacental choriocarcinoma in term nonmolar placenta



Intraplacental choriocarcinoma in term nonmolar placenta

Choriocarcinoma

• Differential Diagnosis:

- Previllous trophoblasts in early gestations
- Persistent Trophoblastic Disease following Complete Mole
 - No villi due to sampling
 - Residual molar implantation site
 - Choice of terminology does not have clinical impact
- Placental Site Trophoblast Tumor (PSTT) or Epithelioid Trophoblast Tumor (ETT)
 - "Syncytiotrophoblast-poor" choriocarcinoma



Mimic of Choriocarcinoma:

Early gestion with trophoblast shell in hematosalpinx/ectopic pregnancy

Complete Hydatidiform Moles (CHM)



Classic Complete Hydatidiform Mole – Genetics

- Diploid with diandry (2p)
 - p57 is absent because it is expressed only from the maternal genome...in cytotrophoblasts and stromal cells



D 2006 Elsevier Inc. Crum CP and Lee KR. Diagnostic Gynecologic and Obstetric Pathology

20%	80%
46,XX or XY	46,XX
Genome-	Genome-
wide	wide LOH
hetero-	
zygosity	

Biparental Complete Hydatidiform Mole

- CHM variant that are *diploid but biparental (1M:1P)*
- Recurrent
- Autosomal Recessive
- Maternal effect -- failure to establish maternal imprint
- Specific trans-acting genes:
 - NALP7/NLRP7 (MIM 609661)
 - 19q13.42
 - Negative regulator of interleukin-1- β , which may in turn regulate inflammatory proteases needed for blastocyst implantation
 - C6orf221 (MIM 611687)
 - 6q13
 - aka Embryonic Stem Cell-associated Transcript 1; ECAT1
 - Member of eutherian oocyte- and embryo-expressed KHDC1/DPPA5/ECAT1/OOEP gene family at 6q13
 - Oocyte specific expression

• As the gestational age increases, the molar villi uniformly grow to macroscopic size, forming grape-like cysts. This entity is so named because of the "water drop" cysts (Greek - "hydatisia") cluster together forming a false conception (Latin "mole").

• Embryonic development does not occur.



Histological Features

- Complete mole ≈ Choriocarcinoma plus villi
- Trophoblast atypia (usually)...yes, even more than usual
- Circumferential trophoblast hyperplasia
- Molar (atypical) implantation site
- Histological features evolve with time
 - Blue myxoid stroma, similar to early normal gestatations
 - Villi have narrow cleft-like invaginations to the stroma
 - Progressive stromal cell death degeneration
 - Vessels without blood may be present very early
 - Then cavitation of villous stroma



- Cavitation
- Absence of fetal vessels



- Trophoblast hyperplasia
 - Circumferential
 - Exuberant

CHM are distinct from the normal progression from proliferation to differentiation



MelCAM | CD146 Ki-67 | MIB1



• Trophoblast atypia

 May range from modest to severe



Molar Implantation Site

- Distinctive easy to see; more atypical than usual
- May be your first clue
- Pitfall: mimics ChorioCa
 or PSTT



"Degenerating" CHM have less atypia and hyperplasia, may be confused with nonmolar hydropic villi.



Early Complete Hydatidiform Mole

Keep et al. Hum Pathol, 1996



Note: Blue myxoid stroma

Pitfall: also found in very early gestations



Note:

Deep cleft-like infolding of trophoblast layer



Note:

Features of both Early and Clasical CHM



Note:

Stromal (and vascular) cell degeneration



Note:

Early cavitation



Note:

Early presentation more common intensively US screened populations

Differential Diagnosis

- Very Early Gestational Sac
- Early Abortus
- Hydropic Abortus
- Partial Mole
- Twin Gestation with Complete Mole as Co-Twin

Early Gestational Sac



Image courtesy of Dr. T. Boyd

Early Gestational Sac



Clue – Never more than a single cavitated villi

Image courtesy of Dr. T. Boyd
Early Gestational Sac



Clue – Symmetric swelling with attenuation (no hyperplasia), without cavitation

Image courtesy of Dr. T. Boyd

Invasive Complete Mole

"Chorioadenoma Destruens"

CHM x Placenta Increta



Things to keep in mind about Invasive Mole

- Not readily detectible by curettage
- More frequent in age > 40 yr and underdeveloped countries
- Hemorrhage may obscure villi grossly
- Vascular space invasion common
- Frequency of persistent or metastatic gestational trophoblastic disease (GTD):
 - CHM >> Invasive Mole > ChorioCA
- Villi may be scarce
- Pathobiologic mechanism unknown

Complete Hydatidiform Mole

in a Twin Gestation



Things to keep in mind about Molar Twins

- Rare
- CHM of interest, but PHM also possible as co-twin
- Pitfall iatrogenic admixture of CHM co-twin by curettage mimics PHM
- Presence of normal co-twin often delays diagnosis
- Higher pre-evacuation β-hCG; clinical symptoms more likely
- Poses obstetrical management issues, but successful deliver possible

Ancillary tools for complete mole

- Genetics
 - Flow cytometry for DNA index (2n or 4n ploidy)
 - Karyotype (46,XX or 46,XY)
 - Microarray
 - SNP analysis may detect genome-wide LOH (uniparental) if derived from single sperm
 - Microsatellite polymorphisms
 - Diandry if parental DNAs collected
- Immunohistochemistry
 - Leverage underlying pathobiology of aberrant imprinting

cyclin-dependent kinase inhibitor 1C (p57, Kip2) (CDKN1C)

- Imprinted, with preferential expression of the maternal allele
- Strong inhibitor of several G1 cyclin/Cdk complexes and a negative regulator of cell proliferation
- Tumor suppressor candidate and plays a role in Beckwith-Wiedemann syndrome
- Part of an imprinted gene region on 11p15.5 with IGF2 and H19



Castrillion et al. Am J Surg Pathol, 2001



Relaxation Of Imprinting In Extra-Villous Trophoblasts

No nuclear staining in villous cytotrophoblasts and villous stromal cells

Murphy's Law for Reproduction – Watch out for unusual p57 staining patterns!!



Twin with CHM Co-Twin



Chimeric/Mosaic Gestation Some behave like CHM Also seen in PHM mimics Placental Mesenchymal Dysplasia Beckwith–Wiedemann syndrome

Partial Hydatidiform Moles





Partial Hydatidiform Mole

• Image courtesy of Dr. T. Boyd

Partial Hydatidiform Mole – Maldeveloped fetuses with 3-4 syndactyly





Images courtesy of Dr. T. Boyd

Partial Hydatidiform Mole

Intermixed Biphasic Population of Villi by Size

proposed stringent threshold for villous enlargement: >2.5 mm



Partial Hydatidiform Mole Have Irregularly Shaped Enlarged Villi



Partial Hydatidiform Mole

Irregular Shapes in Larger Villi





Partial Hydatidiform Mole – Inclusions Reflect Shape Complexity

Partial Hydatidiform Mole

Scattered Cavitation of Larger Villi

my favorite criteria



Partial Hydatidiform Mole

Trophoblastic Hyperplasia

Proliferation commensurate to size & "tagging"



Fetal Development in Partial Mole

Amnion and Chorion



Fetal blood (common) and Embryo (uncommon)



Numerous Nucleated Fetal Red Blood Cells Not Typically Found In CHM

Diploid partial mole mimic (ish CEP17x2, nl p57 IHC)

Chorionic plate mimicking a cavitated villus



Trisomy 21 mimicking partial mole

Dysmorphic villi with dimorphism but without cavitation



Trisomy 13 is a very frequent PHM mimic

Best aneusomy mimic that I've seen was trimsomy 11 (because it has 3 copies of p57 locus, presumable 2 from the father)



Partial Hydatidiform Mole Are Diandric Triploid Gestations Favoring Placental Growth

	Redline et al. <i>Hum Pathol,</i> 1998	Han et al. Am J Surg Pathol, 2020	Various Case Reports
Starting population	Spontaneous abortion (832)	Prenatal screening for aneuploidy	
Refined population	Triploid (65)	Triploid (20)	
Methodology	Karyotype & Microsatellite PCR	Genotype Testing	
Digynic (1P:2M)	Non-molar (31%) Fetal tissue more frequently found	Non-molar (35%)	
Diandric (2P:1M)	Partial mole (61%) phenotypic spectrum including "early", "ancient", "suggestive"	Partial mole (65%) Only ¼ diagnostic by (+) cistern and >2.5 mm ¾ had focal or incomplete phenotype	
Tetraploid Triandric (3P:1M)			Rare cases with features resembling partial mole

Non-molar Triploidy (digynic - 2M1P)

Not dimorphic



Villous sclerosis, without cavitation



Determination of Ploidy for PHM – The Solution, A Helping Hand or Unnecessary?

Methods

- Karyotype
- Flow cytometry DNA analysis
- In situ hybridization
- Microsatellite "fingerprinting"
- Microarray
- Whole genome/exome sequencing

Issues

- Requires living fetal cells
- Needs whole nuclei
- Inconclusive with 1 chromosome
- Complicated without parental DNA
- Bioinformatics
- Bioinformatics
- All:
 - Instrumentation, Cost, & Time
 - Parent Of Origin
 - Data you didn't seek or on your radar

Do you really need copy number analysis?

• **RESULTS**:

- 260 cases of PHMs
- Blinded pathologic review showed sensitivity of 88% and specificity of 95% in diagnosing PHMs with histology alone vs. histology with ancillary testing.
- 100% of PHMs (n=56) expressed p57 staining and 100% of CHMs (n=57) had absent staining
- 145 subjects had clinical follow-up data
 - 16 diagnosed with GTD (by serum hCG).
 - 13 cases of cases of clinical GTN histologically resembling "retained placenta"
 - Only 2 had adverse outcomes (ETT and ChorioCA)

"Persistent" PHM looks like "funny" retained POC



The exception to the rule

International Journal of Gynecological Pathology 27:247–251, Lippincott Williams & Wilkins, Baltimore © 2008 International Society of Gynecological Pathologists

Case Report

Intraplacental Choriocarcinoma Arising in a Second Trimester Placenta With Partial Hydatidiform Mole

Fabiola Medeiros, M.D., Michael J. Callahan, M.D., Julia A. Elvin, M.D., Ph.D., David M. Dorfman, M.D., Ph.D., Ross S. Berkowitz, M.D., and Bradley J. Quade, M.D., Ph.D.



Partial Hydatidiform Mole

P57 expression retained in PHM (A) and lost in ChorioCA (B)



Triploid gestation (yellow peak) in placental



Metastasis From Intraplacental Choriocarcinoma Arising In Partial Mole



Diagnosing Possible Molar Gestations in General Surgical Pathology Practice



A Practical Approach to Molar Pregnancies

- Absence of villi does not exclude molar gestation... but it moves it down the list
- Risk of Persistent GTD (including recurrence or metastasis)
 - CHD >> PHM (~20% v. ~2%, but metastatic risk closer to normal gestations for PHM)
- Strategy should focus on finding every CHM
 - Use p57 liberally...it works well, is cheap, and adds little delay
 - Ask for help if the p57 doesn't make sense (you may have found a chimeric or mosaic gestion with the potential to behave like a CHD biologically)
 - Use genetic information when you have it, after excluding a CHM
 - Some aneusomies (e.g., +13, +11, +21) are excellent mimics of PHM
 - Triploidy ≠ PHM... but 3n plus dysmorphic villi (suggestive histology) is sufficient, in my opinion
 - I don't wait for karyotype or microarray in most cases (volume too high), but I add my name to cytogenetic report distribution and check it later
 - Non-canonical p57 might be twin or chimera/mosaic



Timely Topic –

Maternal & Placental SARS-CoV-2

Fast Breaking Story

- From non-traditional outlets
 - Public (news) media
 - Social media
 - Professional list serves/bulletin boards, word-of-mouth
- Pre-publication release (not peer reviewed)...
 - the early standard practice for pandemic



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Fig. 3. The life cycle of SARS-CoV-2 in host cells; begins its life cycle when S protein binds to the cellular receptor ACE2. After receptor binding, the conformation change in the S protein facilitates viral envelope fusion with the cell membrane through the endosomal pathway. Then SARS-CoV-2 releases RNA into the host cell. Genome RNA is translated into viral replicase polyproteins pp1a and 1ab, which are then cleaved into small products by viral proteinases. The polymerase produces a series of subgenomic mRNAs by discontinuous transcription and finally translated into relevant viral proteins. Viral proteins and genome RNA are subsequently assembled into virions in the ER and Golgi and then transported via vesicles and released out of the cell. ACE2, angiotensin-converting enzyme 2; ER, endoplasmic reticulum; ERGIC, ER–Golgi intermediate compartment.



M.A. Shereen et al. J Adv Res 24 (2020) 91–98

SARS-CoV-2 Cell **Entry Depends on** ACE2 and TMPRSS2 and Is Blocked by a **Clinically Proven Protease Inhibitor**

Hoffmann et al., 2020, Cell 181, 271–280 April 16, 2020 ^a 2020 Elsevier Inc. https://doi.org/10.1016/j.cell.2020.02.052


Transmission to the fetus and neonate:

How often and by what mechanism(s)?

- In utero transplacental
- Intra-partem vaginal contact
- Post-partem breast milk

Early Online Release



Current Issue Available Issues Early Online Release

Alerts for the Journal

Click <u>here</u> to get an email alert for every new issue of

Archives of Pathology & Laboratory Medicine David A. Schwartz, MD, MS Hyg
The author has no relevant financial interest in the products or companies described in this article.
Corresponding author: David A. Schwartz, MD, MS Hyg, Department of Pathology, Medical College of Georgia, Augusta University,
1950 Grace Arbor Court, Atlanta, GA 30329 (email: davidalanschwartz@gmail.com).
The emergence of a novel coronavirus, termed SARS-CoV-2, and the potentially life-threating respiratory disease that it can
produce, COVID-19, has rapidly spread across the globe creating a massive public health problem. Previous epidemics of
many emerging viral infections have typically resulted in poor obstetrical outcomes including maternal morbidity and mortality,
maternal-fetal transmission of the virus, and perinatal infections and death. This communication reviews the effects of two
previous coronavirus infections - severe acute respiratory yondrome (SARS) caused by SARS-CoV and Middle East
respiratory syndrome (MERS) caused by MERS-CoV - on pregnancy outcomes. In addition, it analyzes literature describing 38
pregnant women with COVID-19 and their newborns in China to assess the effects of SARS-CoV-2 on the mothers and infants
including clinical, laboratory and virologic data, and the transmissibility of the virus from mother to fetus. This analysis reveals
that unlike coronavirus infections of pregnant women caused by SARS and MERS, there were no confirmed caused of saRS and MERS, there were no confirmed causes of

Add to Favorites A Share Article & Export Citations Track Citations (RSS | Email) Permissions

<u>PDF</u>

David A. Schwartz (2020) An Analysis of 38 Pregnant Women with COVID-19, Their Newborn Infants, and Maternal-Fetal Transmission of SARS-CoV-2: Maternal Coronavirus Infections and Pregnancy Outcomes. Archives of Pathology & Laboratory Medicine In-Press.

An Analysis of 38 Pregnant Women with COVID-19, Their Newborn Infants, and Maternal-Fetal

Transmission of SARS-CoV-2: Maternal Coronavirus Infections and Pregnancy Outcomes

intrauterine transmission of SARS-CoV-2 from mothers with COVID-19 to their fetuses. All neonatal specimens tested, including in some cases placentas, were negative by rt-PCR for SARS-CoV-2. At this point in the global pandemic of COVID-19 infection there is no evidence that SARS-CoV-2 undergoes intrauterine or transplacental transmission from infected pregnant women to their fetuses. Analysis of additional cases is necessary to determine if this remains true.

Journal Information

© 2020 College of American Pathologists

Article Citation:

Early Online Release

https://doi.org/10.5858/arpa.2020-0901-SA

 Online ISSN:
 1543-2165

 Print ISSN:
 0003-9985

 Frequency:
 Monthly



Cardiovascular Medicine

syncytiotrophoblast cells at the maternal-fetal interface of the placenta. Histological

New England Study

Modern Pathology (2020) 33:2092-2103 https://doi.org/10.1038/s41379-020-0639-4

ARTICLE

SARS-CoV-2 can infect the placenta and is not associated with specific placental histopathology: a series of 19 placentas from COVID-19-positive mothers

Jonathon L. Hecht¹ · Bradley Quade² · Vikram Deshpande³ · Mari Mino-Kenudson 3 · David T. Ting 4,5 · Niyati Desai⁴ · Beata Dygulska⁶ · Taryn Heyman⁷ · Carolyn Salafia⁸ · Dejun Shen 9 · Sara V. Bates¹⁰ · Drucilla J. Roberts 0 ³

XUSCAP

Received: 19 June 2020 / Revised: 24 July 2020 / Accepted: 24 July 2020 / Published online: 2 August 2020 © The Author(s), under exclusive licence to United States & Canadian Academy of Pathology 2020

- 19 COVID-19 exposed placentas
- ACE2 in syncytiotrophoblasts (ST) with polarized distribution skewed to *basal* side
- TMPRSS2 only present weakly in the villous endothelium and rarely in the ST
- Combined expression pattern may limit infection
- 2/19 infected placenta ("cherry picked"), no specific pathogy

ACE2



Accumulation of More Case: Mother and Baby both COVID-19+

Spike protein IHC



Spike protein mRNA ISH



COVID-19 Placentitis

Various Sized Clusters Of Aggregated Villi



Chronic Histiocytic Intervillositis & Early Placental Infarction/Intervillous Fibrin



COVID-19 Placentitis As Variant of Chronic Histiocytic Intervillositis

Macrophages (PU.1)



Lymphocytes (LCA/CD45)



Take Away Messages

- Placental infection uncommon in most CoVID-19(+) mothers
- Mechanism (and clinical implications) of placental infection partially understood
 - Maternal viremia low
 - ACE2 present in syncytiotrophoblasts...mostly on stromal side...and very low TMPRSS2, potentially limiting placental infection
- Role of ancillary testing for placenta not established...but Anti-Spike IHC likely to be helpful
- BOLO for emerging pattern of histopathology when SARS-CoV-2 infection present
 - Atypical chronic histiocytic intervillositis with
 - Mixed inflammatory infiltrate with PMN and macrophages
 - Necrosis / infarction
 - Perivillous fibrin deposition



KEEP CALM AND WASH YOUR HANDS

www.odc.gowhandwashing

U.S. Department of Health and Human Services Centers for Disease Control and Prevention



Acknowledgements

- BWH / New England Trophoblast Disease Center
 - Ross Berkowitz
 - Neil Horowitz
 - Kevin Elias
 - Fabiola Medeiros
 - Rinda Soong
- Harvard
 - Dru Roberts
 - Johnathan Hecht



Thank You and Best Wishes for the New Year